Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. CEO Troy Wilson will join a virtual fireside chat on February 17, 2022, at 12:40 p.m. PT. The event will be accessible via a live audio webcast on Kura's website, with a replay available afterward. Kura focuses on precision cancer medicines and is advancing its pipeline of cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC patients.

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11^th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022.

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also developing KO-2806, a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When is Kura Oncology's participation in the SVB Leerink Global Healthcare Conference?

Kura Oncology will participate on February 17, 2022.

Who will represent Kura Oncology at the conference?

Troy Wilson, CEO of Kura Oncology, will represent the company.

What time is Kura Oncology's virtual fireside chat?

The fireside chat is scheduled for 12:40 p.m. PT / 3:40 p.m. ET.

How can I access the Kura Oncology fireside chat?

The chat will be available via a live audio webcast on Kura's website.

What treatments is Kura Oncology currently developing?

Kura is developing KO-539 for AML and Tipifarnib for HRAS mutant HNSCC.